Teleflex Aktsia

Teleflex EBITDA

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Teleflex (TFX) seisuga 5. aug 2026 on 255,80 M USD. Eelmisel aastal oli EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) 159,02 M USD — muutus 60,86% (kõrgem).

EBITDA

255,80 MUSD

YoY

60,86%

Viimati uuendatud:

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Teleflex on 2026 255,80 M USD. EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Teleflex oli 2025 159,02 M USD. See väheneb 60,86% kõrgem võrreldes eelmise aastaga.
Access this data via the Eulerpool API

Teleflex Aktsiate analüüs

Mida Teleflex teeb? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care. The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors. Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients. In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths. The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources. The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies. With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths. The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators. The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials. The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents. Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused Teleflex aktsia kohta

Teleflex EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) on 2026. aastal 255,80 M USD.

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) ettevõttest Teleflex muutus 159,02 M USD-st 255,80 M USD-ks, mis vastab 60,86% muutusele. Väärtus on kõrgem kui eelmisel aastal.

Eulpoolist leiate EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) Teleflex täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

EBITDA mõõdab operatiivset sooritust enne finantsstruktuuri, maksustamiskeskkonna ja mitterahalist amortisatsioonimaksude mõju.

EBITDA = EBIT + amortisatsioon ja amortisatsioon

EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) USD on investorite jaoks määrav tegur. Selle näitaja muutused võivad signaliseerida põhialuste paranemist või halvenemist, mõjutades otseselt aktsia hinda. Eulpoolis saate EBITDA (kasum enne intresse, makse, amortisatsiooni ja amortisatsiooni) Teleflex ajaloolist arengut ja reaalajas andmeid jälgida.

Access this data via the Eulerpool API

Kasumi- ja kahjumiaruanne — Teleflex

Kõik finantsnäitajad — Teleflex